Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET
Company Participants
Ned Mitchell - IR
Rui Avelar - Chief Medical Officer & Head, Research & Development
David Moatazedi - President, CEO & Director
Sandra Beaver - CFO
Conference Call Participants
Louise Chen - Cantor Fitzgerald
Annabel Samimy - Stifel, Nicolaus & Company
Marc Goodman - Leerink Partners
Navann Dietschi - BNP Paribas Exane
Uy Ear - Mizuho Securities
Douglas Tsao - H.C. Wainwright & Co.
Operator
Good afternoon, and welcome to the Evolus Third Quarter 2023 Earnings Conference Call. [Operator Instructions].
I would now like to turn the conference over to your host, Mr. Ned Mitchell from Investor Relations. Ned?
Ned Mitchell
Thank you, operator, and welcome to everyone joining us on today's call. With me today are David Moatazedi, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer and Head of R&D; and Sandra Beaver, Chief Financial Officer.
Our prepared remarks today will include forward-looking statements within the meaning of United States securities laws and management may make additional forward-looking statements in response to your questions. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the company's business, strategy, operations or financial performance. A detailed discussion of the risks and uncertainties that the company faces is contained in its annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Actual results may differ materially from those expressed in or implied by the forward-looking statements. The company undertakes no obligation to update or review any estimate, projection or forward-looking statements.
Additionally, today's discussion will include non-GAAP financial measures, which be considered in addition to that not as a substitute for or in isolation from our GAAP results. A reconciliation of GAAP to non-GAAP results may be found in our earnings release, which was furnished with our Form 8-K filed today with the SEC and on our Investor Relations website at evolus.com. Following the conclusion of today's call, a replay will be available on our website at evolus.com.
With that, I'll turn over to David.
David Moatazedi
Thank you, Ned. We are very pleased to see the increasing momentum of our business driven by strong execution, which has translated into record quarterly revenue and record low cash burn. -- in what is historically the seasonally lowest for the injectible category. Our focus has been consistent and intentional. We're building a beauty brand for the younger generation, which represents the fastest-growing segment of the neurotoxin market.